
Loading, please wait...

Loading, please wait...

Valproic acid (VPA) serves primarily as an anticonvulsant and a cornerstone mood stabilizer for bipolar disorder. However, emerging preclinical evidence suggests its utility extends further. A comprehensive systematic review and meta-analysis recently explored valproic acid antidepressant effects in rodent models of stress-induced depression. These findings offer significant insights into the potential neuroprotective and mood-regulating properties of this established medication.
The research team examined data from several validated behavioral assays, including the Forced Swimming Test (FST), Open Field Test (OFT), and Sucrose Preference Test (SPT). Their systematic evaluation included sixteen separate experiments for the FST alone. Consequently, the researchers identified a consistent pattern of improved behavioral outcomes following VPA administration.
Meta-analysis results showed that VPA significantly reduced the percentage of immobility in the FST. Specifically, the standardized mean difference (SMD) was -0.93, indicating a strong effect in lowering stress-related despair compared to untreated groups. Furthermore, results from nine experiments in the Sucrose Preference Test demonstrated that VPA increased the animals' desire for rewards. This suggests that the drug effectively counters anhedonia, which is a core symptom of clinical depression.
Regarding dosage, the study highlighted that administering VPA at 300 mg/kg/day via injection for four consecutive weeks significantly decreased depressive symptoms. Additionally, horizontal and vertical movement scores in the Open Field Test increased, implying higher activity levels and reduced anxiety. However, the analysis of the Novel Object Recognition (NOR) test showed no significant effect on the animals' ability to identify new objects. Therefore, while VPA impacts mood and motivation, its effect on specific memory recognition tasks may be limited in these stress models.
Despite these promising results, the researchers noted significant heterogeneity and a risk of publication bias. They advised caution when interpreting these findings for immediate clinical translation. Future studies should focus on refining the therapeutic windows and understanding the precise molecular mechanisms, such as histone deacetylase (HDAC) inhibition, behind these antidepressant-like actions.
The meta-analysis found that a dosage of 300 mg/kg/day, administered via injection for four weeks, significantly reduced depressive-like behaviors in the rodent models studied.
Results from the Sucrose Preference Test indicated that valproic acid significantly increased the animals' preference for sucrose water, suggesting it may help reverse stress-induced anhedonia.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
1. Goudarzi M et al. Valproic acid effects on stress-induced depression-like behavior in rodent models: a systematic review and meta-analysis. Stress. 2026 Dec 31. doi: 10.1080/10253890.2026.2641561. PMID: 41826267.
2. Goudarzi M et al. Valproic acid administration exerts protective effects against stress-related anhedonia in rats. J Chem Neuroanat. 2020 Apr;105:101768. doi: 10.1016/j.jchemneu.2020.101768.
3. Lima MG et al. Valproate as an antidepressant in major depressive disorder: a systematic review. Journal of Affective Disorders. 2017;218:230-236.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A meta-analysis explores valproic acid antidepressant effects in rodents, finding significant reductions in stress-induced despair and anhedonia at 300 mg/k...
5 months ago

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today